|1.||Hayden, Michael R: 8 articles (05/2015 - 01/2011)|
|2.||Albrecht, Steffen: 7 articles (01/2014 - 08/2004)|
|3.||Ehrnhoefer, Dagmar E: 6 articles (05/2015 - 01/2011)|
|4.||Graham, Rona K: 5 articles (04/2015 - 12/2011)|
|5.||LeBlanc, Andréa C: 5 articles (01/2014 - 04/2007)|
|6.||Franciosi, Sonia: 4 articles (05/2015 - 01/2012)|
|7.||Deng, Yu: 4 articles (04/2015 - 01/2012)|
|8.||LeBlanc, Andrea C: 4 articles (01/2015 - 08/2004)|
|9.||Su, Xiao-Dong: 4 articles (01/2015 - 10/2010)|
|10.||Hannoush, Rami N: 4 articles (12/2012 - 01/2012)|
08/01/2001 - "We demonstrated that the hTERT/rev-caspase-6 construct induced apoptosis in hTERT-positive malignant glioma cells, but not in hTERT-negative astrocytes, fibroblasts, and alternative lengthening of telomeres cells. "
07/01/2004 - "These results suggest that agents, which induce apoptosis without inhibiting telomerase activity are a promising counterpart to combine with hTERT/rev-caspase-6 therapy for the management of malignant gliomas."
08/01/2001 - "Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter."
02/23/2001 - "We assumed that FTY720 induced FAK dephosphorylation and cut off the FAK-PI3-kinase pathway resulting in the induction of apoptosis via caspase-6 activation in these glioma cells."
07/01/2004 - "Recently, we have reported the therapeutic efficacy of delivering initiator caspase (caspase-8) or executioner active caspase (rev-caspase-6) to telomerase-positive malignant glioma cells using the human telomerase reverse transcriptase (hTERT) gene promoter system (hTERT/caspase-8 or hTERT/rev-caspase-6). "
|2.||Ganglion Cysts (Ganglion)
07/20/2011 - "We also show that caspase-6 inhibition resulted in improved ganglion cell survival and robust axonal regeneration following optic nerve injury in adult rats. "
07/20/2011 - "Treatment of rat retinal whole mounts with Z-VEID-FMK, a selective inhibitor of caspase-6, enhanced ganglion cell survival. "
07/14/2000 - "Specific inhibitors of caspase-3 and caspase-6 showed a similar ability to BAF in preventing EDBA mediated ganglion cell loss, whereas inhibitors of caspase-8 and caspase-9 were not able to rescue EDBA treated ganglion cells. "
|3.||Colorectal Neoplasms (Colorectal Cancer)
09/01/2006 - "We also analyzed caspase-6 expression by immunohistochemistry, and found that caspase-6 was expressed in 60% of the gastric cancers and 90% of the colorectal cancers. "
12/01/2014 - "Silencing STMN1 also significantly improved chemoresponse to the classical colorectal cancer therapeutic agent, 5FU, via a novel caspase-6 (CASP6)-dependent mechanism. "
09/01/2006 - "To explore the possibility that the genetic alterations of CASP, which encodes caspase-6, might be involved in the development of human cancers, we analyzed the entire coding region and all splice sites of the human CASP6 gene for the detection of somatic mutations in 100 colorectal carcinomas and 50 gastric carcinomas. "
|4.||Optic Nerve Injuries
12/05/2012 - "In vitro, we show that genetic deletion of Caspase-3 is fully protective against sensory axon degeneration initiated by trophic factor withdrawal, but not injury-induced Wallerian degeneration, and we define a biochemical cascade from prosurvival Bcl2 family regulators to Caspase-9, then Caspase-3, and then Caspase-6. "
|1.||Caspase 3 (Caspase-3)
|2.||Caspase 8 (Caspase-8)
|5.||Telomerase (Telomerase Reverse Transcriptase)
|7.||Proteins (Proteins, Gene)
|2.||Photochemotherapy (Photodynamic Therapy)